|
1
|
Rajan F and Bhatt A: Management of
peritoneal metastases-cytoreductive surgery, HIPEC and beyond.
Springer. 2018.
|
|
2
|
Yan TD, Welch L, Black D and Sugarbaker
PH: A systematic review on the efficacy of cytoreductive surgery
combined with perioperative intraperitoneal chemotherapy for
diffuse malignancy peritoneal mesothelioma. Ann Oncol. 18:827–834.
2007.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Goéré D, Passot G, Gelli M, Levine EA,
Bartlett DL, Sugarbaker PH and Glehen O: Complete cytoreductive
surgery plus HIPEC for peritoneal metastases from unusual cancer
sites of origin: Results from a worldwide analysis issue of the
peritoneal surface oncology group international (PSOGI). Int J
Hyperthermia. 33:520–527. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Hotouras A, Desai D, Bhan C, Murphy J,
Lampe B and Sugarbaker PH: Heated IntraPEritoneal chemotherapy
(HIPEC) for patients with recurrent ovarian cancer: A systematic
literature review. Int J Gynecol Cancer. 26:661–670.
2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kireeva GS, Gafton GI, Guseynov KD,
Senchik KY, Belyaeva OA, Bespalov VG, Panchenko AV, Maydin MA and
Belyaev AM: HIPEC in patients with primary advanced ovarian cancer:
Is there a role? A systematic review of short- and long-term
outcomes. Surg Oncol. 27:251–258. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Honoré C, Goéré D, Macovei R, Colace L,
Benhaim L and Elias D: Peritoneal carcinomatosis from unusual
cancer origins: Is there a role for hyperthermic intraperitoneal
chemotherapy? J Visc Surg. 153:101–107. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Mulier S, Claes JP, Dierieck V, Amiel JO,
Pahaut JP, Marcelis L, Bastin F, Vanderbeeken D, Finet C, Cran S
and Velu T: Survival benefit of adding hyperthermic IntraPEritoneal
chemotherapy (HIPEC) at the different time-points of treatment of
ovarian cancer: Review of evidence. Curr Pharm Des. 18:3793–3803.
2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bae JH, Lee JM, Ryu KS, Lee YS, Park YG,
Hur SY, Ahn WS and Namkoong SE: Treatment of ovarian cancer with
paclitaxel- or carboplatin-based intraperitoneal hyperthermic
chemotherapy during secondary surgery. Gynecol Oncol. 106:193–200.
2007.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Deraco M, Kusamura S, Virzì S, Puccio F,
Macrì A, Famulari C, Solazzo M, Bonomi S, Iusco DR and Baratti D:
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
as upfront therapy for advanced epithelial ovarian cancer:
Multi-institutional phase-II trial. Gynecol Oncol. 122:215–220.
2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Vergote I, Tropé CG, Amant F, Kristensen
GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ,
Panici PB, et al: Neoadjuvant chemotherapy or primary surgery in
stage IIIC or IV ovarian cancer. N Engl J Med. 363:943–953.
2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chi DS, Eisenhauer EL, Zivanovic O, Sonoda
Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C and
Barakat RR: Improved progression-free and overall survival in
advanced ovarian cancer as a result of a change in surgical
paradigm. Gynecol Oncol. 114:26–31. 2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Armstrong DK, Bundy B, Wenzel L, Huang HQ,
Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA:
Gynecologic Oncology Group. Intraperitoneal cisplatin and
paclitaxel in ovarian cancer. N Engl J Med. 354:34–43.
2006.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Eisenkop SM, Spirtos NM, Friedman RL, Lin
WC, Pisani AL and Perticucci S: Relative influences of tumor volume
before surgery and the cytoreductive outcome on survival for
patients with advanced ovarian cancer: A prospective study. Gynecol
Oncol. 90:390–396. 2003.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW,
Nam BH and Park SY: HIPEC for Ovarian Cancer Collaborators.
Survival after hyperthermic intraperitoneal chemotherapy and
primary or interval cytoreductive surgery in ovarian cancer: A
randomized clinical trial. JAMA Surg. 157:374–383. 2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
van Driel WJ, Koole SN, Sikorska K,
Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT,
van der Velden J, Arts HJ, Massuger LFAG, et al: Hyperthermic
intraperitoneal chemotherapy in ovarian cancer. N Engl J Med.
378:230–240. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Antonio CCP, Alida GG, Elena GG, Rocío GS,
Jerónimo MG, Luis ARJ, Aníbal ND, Francisco BV, Jesús GRÁ, Pablo RR
and José GM: Cytoreductive surgery with or without HIPEC after
neoadjuvant chemotherapy in ovarian cancer: A Phase 3 clinical
trial. Ann Surg Oncol. 29:2617–2625. 2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Koole SN, Kieffer JM, Sikorska K, Schagen
van Leeuwen JH, Schreuder HWR, Hermans RH, de Hingh IH, van der
Velden J, Arts HJ, van Ham MAPC, et al: Health-related quality of
life after interval cytoreductive surgery with or without
hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with
stage III ovarian cancer. Eur J Surg Oncol. 47:101–107.
2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Koole SN, van Lieshout C, van Driel WJ,
van Schagen E, Sikorska K, Kieffer JM, Schagen van Leeuwen JH,
Schreuder HWR, Hermans RH, de Hingh ICH, et al: Cost effectiveness
of interval cytoreductive surgery with hyperthermic intraperitoneal
chemotherapy in stage III ovarian cancer on the basis of a
randomized phase III trial. J Clin Oncol. 37:2041–2050.
2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
El Hajj H, Vanseymortier M, Hudry D,
Bogart E, Abdeddaim C, Leblanc E, Le Deley MC and Narducci F:
Rationale and study design of the CHIPPI-1808 trial: A phase III
randomized clinical trial evaluating hyperthermic intraperitoneal
chemotherapy (HIPEC) for stage III ovarian cancer patients treated
with primary or interval cytoreductive surgery. ESMO Open.
6(100098)2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Koole S, van Stein R, Sikorska K, Barton
D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A,
Colombo PE, et al: Primary cytoreductive surgery with or without
hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage
III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized
clinical trial. Int J Gynecol Cancer. 30:888–892. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Spiliotis J, Halkia E, Lianos E, Kalantzi
N, Grivas A, Efstathiou E and Giassas S: Cytoreductive surgery and
HIPEC in recurrent epithelial ovarian cancer: A prospective
randomized phase III study. Ann Surg Oncol. 22:1570–1575.
2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zivanovic O, Chi DS, Zhou Q, Iasonos A,
Konner JA, Makker V, Grisham RN, Brown AK, Nerenstone S, Diaz JP,
et al: Secondary cytoreduction and carboplatin hyperthermic
intraperitoneal chemotherapy for platinum-sensitive recurrent
ovarian cancer: An MSK team ovary phase II study. J Clin Oncol.
39:2594–2604. 2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Jamison PM, Altekruse SF, Chang JT, Zahn
J, Lee R, Noone AM and Barroilhet L: Site-specific factors for
cancer of the corpus uteri from SEER registries: Collaborative
stage data collection system, version 1 and version 2. Cancer.
120:3836–3845. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tempfer CB, Kern P, Dogan A, Hilal Z and
Rezniczek GA: Cytoreductive surgery with hyperthermic
intraperitoneal chemotherapy for endometrial cancer-derived
peritoneal metastases: A systematic review. Clin Exp Metastasis.
36:321–329. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Gomes David M, Bakrin N, Salleron J,
Kaminsky MC, Bereder JM, Tuech JJ, Lehmann K, Mehta S, Glehen O and
Marchal F: Cytoreductive surgery (CRS) plus hyperthermic
intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of
endometrial cancer with peritoneal metastases: A
multi-institutional study from PSOGI and BIG RENAPE groups. BMC
Surg. 22(1)2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wong LCK, Li Z, Fan Q, Tan JW, Tan QX,
Wong JSM, Ong CJ and Chia CS: Cytoreductive surgery (CRS) with
hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal
sarcomatosis-A systematic review and meta-analysis. Eur J Surg
Oncol. 48:640–648. 2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Anaya DA, Lahat G, Liu J, Xing Y, Cormier
JN, Pisters PW, Lev DC and Pollock RE: Multifocality in
retroperitoneal sarcoma: A prognostic factor critical to surgical
decision-making. Ann Surg. 249:137–142. 2009.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Bilimoria MM, Holtz DJ, Mirza NQ, Feig BW,
Pisters PW, Patel S, Pollock RE, Benjamin RS, Papadopoulos NE,
Plager C, et al: Tumor volume as a prognostic factor for
sarcomatosis. Cancer. 94:2441–2446. 2002.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Duzgun O and Kalin M: Is cytoreductive
surgery possible in cervical cancer peritoneal carcinomatosis? Clin
Med Insights Oncol. 15(11795549211065308)2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lantsman T, Lepe M, Garrett L, Goodman M
and Shea M: Management of recurrent cervical cancer with peritoneal
carcinomatosis with HIPEC. Gynecol Oncol Rep.
39(100909)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gamboa AC, Lee RM, Turgeon MK, Zaidi MY,
Kimbrough CW, Grotz TE, Leiting J, Fournier K, Lee AJ, Dineen SP,
et al: Implications of postoperative complications for survival
after cytoreductive surgery and HIPEC: A multi-institutional
analysis of the US HIPEC collaborative. Ann Surg Oncol.
27:4980–4995. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Sugarbaker PH: Survival of large volume
recurrent endometrial cancer with peritoneal metastases treated by
cytoreductive surgery, HIPEC and EPIC. Report of a case. Int J Surg
Case Rep. 80(105669)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
de Bree E, Romanos J, Michalakis J,
Relakis K, Georgoulias V, Melissas J and Tsiftsis DD:
Intraoperative hyperthermic intraperitoneal chemotherapy with
docetaxel as second-line treatment for peritoneal carcinomatosis of
gynaecological origin. Anticancer Res. 23:3019–3027.
2003.PubMed/NCBI
|
|
34
|
Croke JM and El-Sayed S: Multidisciplinary
management of cancer patients: Chasing a shadow or real value? An
overview of the literature. Curr Oncol. 19:e232–e238.
2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Berardi R, Morgese F, Rinaldi S, Torniai
M, Mentrasti G, Scortichini L and Giampieri R: Benefits and
limitations of a multidisciplinary approach in cancer patient
management. Cancer Manag Res. 12:9363–9374. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Falzone L, Scandurra G, Lombardo V,
Gattuso G, Lavoro A, Distefano AB, Scibilia G and Scollo P: A
multidisciplinary approach remains the best strategy to improve and
strengthen the management of ovarian cancer (review). Int J Oncol.
59(53)2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Aletti GD, Garbi A, Messori P, Achilarre
MT, Zanagnolo V, Rizzo S, Alessi S, Bocciolone L, Landoni F, Biffi
, et al: Multidisciplinary approach in the management of
advanced ovarian cancer patients: A personalized approach. Results
from a specialized ovarian cancer unit. Gynecol Oncol. 144:468–473.
2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Bhatt A, de Hingh I, Van Der Speeten K,
Hubner M, Deraco M, Bakrin N, Villeneuve L, Kusamura S and Glehen
O: HIPEC methodology and regimens: The need for an expert
consensus. Ann Surg Oncol. 28:9098–9113. 2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Cline MS, Liao RG, Parsons MT, Paten B,
Alquaddoomi F, Antoniou A, Baxter S, Brody L, Cook-Deegan R, Coffin
A, et al: BRCA challenge: BRCA exchange as a global resource for
variants in BRCA1 and BRCA2. PLoS Genet.
14(e1007752)2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Gadducci A, Guarneri V, Peccatori FA,
Ronzino G, Scandurra G, Zamagni C, Zola P and Salutari V: Current
strategies for the targeted treatment of high-grade serous
epithelial ovarian cancer and relevance of BRCA mutational status.
J Ovarian Res. 12(9)2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Lavoro A, Scalisi A, Candido S, Zanghì GN,
Rizzo R, Gattuso G, Caruso G, Libra M and Falzone L: Identification
of the most common BRCA alterations through analysis of germline
mutation databases: Is droplet digital PCR an additional strategy
for the assessment of such alterations in breast and ovarian cancer
families? Int J Oncol. 60(58)2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Madariaga A, Lheureux S and Oza AM:
Tailoring ovarian cancer treatment: implications of BRCA1/2
mutations. Cancers (Basel). 11(416)2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Safra T, Grisaru D, Inbar M, Abu-Abeid S,
Dayan D, Matceyevsky D, Weizman A and Klausner JM: Cytoreduction
surgery with hyperthermic intraperitoneal chemotherapy in recurrent
ovarian cancer improves progression-free survival, especially in
BRCA-positive patients-a case-control study. J Surg Oncol.
110:661–665. 2014.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Oza AM, Cook AD, Pfisterer J, Embleton A,
Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P,
Cervantes A, et al: Standard chemotherapy with or without
bevacizumab for women with newly diagnosed ovarian cancer (ICON7):
Overall survival results of a phase 3 randomised trial. Lancet
Oncol. 16:928–936. 2015.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Monk BJ, Huang HQ, Burger RA, Mannel RS,
Homesley HD, Fowler J, Greer BE, Boente M, Liang SX and Wenzel L:
Patient reported outcomes of a randomized, placebo-controlled trial
of bevacizumab in the front-line treatment of ovarian cancer: A
gynecologic oncology group study. Gynecol Oncol. 128:573–578.
2013.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Walker JL, Brady MF, Wenzel L, Fleming GF,
Huang HQ, DiSilvestro PA, Fujiwara K, Alberts DS, Zheng W, Tewari
KS, et al: Randomized trial of intravenous versus intraperitoneal
chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG
oncology/gynecologic oncology group study. J Clin Oncol.
37:1380–1390. 2019.PubMed/NCBI View Article : Google Scholar
|
